Citations

Clear

6273 citation(s) found for "To, Andrew".

Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis
Dubey, Divyanshu , Pittock, Sean J. , Kelly, Cecilia R. , McKeon, Andrew , López‐Chiriboga, A. Sebastian , Lennon, Vanda A. , Gadoth, Avi , Bryant, Sandra C. , Klein, Christopher J. , Aksamit, Allen J. , Toledano, Michel , Tillema, Jan‐Mendelt , Smith, Carin Y. , Pittock, S J , Klein, Christopher J , McKeon, Andrew , Dubey, Divyanshu , Boeve, Bradley F. , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | January 2, 2018 | Volume: 83 | Issue: 1 | Pages: 166-177

10.1002/ana.25131 | PMID 29293273 Get It

Objective To evaluate the incidence and prevalence of autoimmune encephalitis and compare it to that of infectious encephalitis. Methods We performed a population‐based comparative study of the incidence and prevalence of autoimmune and infectious encephalitis in Olmsted County, Minnesota. Autoimmune encephalitis diagnosis and subgroups were defined by 2016 diagnostic criteria, and infectious encephalitis diagnosis required a confirmed infectious pathogen. Age‐ and sex‐adjusted prevalence and incidence rates were calculated. Patients with encephalitis of uncertain etiology were excluded. Results The prevalence of autoimmune encephalitis on January 1, 2014 of 13.7/100,000 was not significantly different from that of all infectious encephalitides (11.6/100,000; p = 0.63) or the viral subcategory (8.3/100,000; p = 0.17). The incidence rates (1995–2015) of autoimmune and infectious encephalitis were 0.8/100,000 and 1.0/100,000 person‐years, respectively ( p = 0.58). The number of relapses or recurrent hospitalizations was higher for autoimmune than infectious encephalitis ( p = 0.03). The incidence of autoimmune encephalitis increased over time from 0.4/100,000 person‐years (1995–2005) to 1.2/100,000 person‐years (2006–2015; p = 0.02), attributable to increased detection of autoantibody‐positive cases. The incidence (2.8 vs 0.7/100,000 person‐years, p = 0.01) and prevalence (38.3 vs 13.7/100,000, p = 0.04) of autoimmune encephalitis was higher among African Americans than Caucasians. The prevalence of specific neural autoantibodies was as follows: myelin oligodendrocyte glycoprotein, 1.9/100,000; glutamic acid decarboxylase 65, 1.9/100,000; unclassified neural autoantibody, 1.4/100,000; leucine‐rich glioma‐inactivated protein 1, 0.7/100,000; collapsin response‐mediator protein 5, 0.7/100,000; N‐methyl‐D‐aspartate receptor, 0.6/100,000; antineuronal nuclear antibody type 2, 0.6/100,000; and glial fibrillary acidic protein α, 0.6/100,000. Interpretation This study shows that the prevalence and incidence of autoimmune encephalitis are comparable to infectious encephalitis, and its detection is increasing over time. Ann Neurol 2018;83:166–177
Phase 1 trial of ontuxizumab (MORAb‐004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)
Norris, Robin E. , Fox, Elizabeth , Ralya, Andrew T., Liu, Xiaowei W., Weigel, Brenda J. , Reid, Joel M. , Ralya, Andrew, Minard, Charles G. , Norris, Robin E

Mayo Clinic

Pediatric Blood & Cancer | January 2, 2018 | Volume: 65 | Issue: 5 | Pages: No page available

10.1002/pbc.26944 | PMID 29292843 Get It

AbstractBackgroundOntuxizumab is a humanized IgG monoclonal antibody that targets the cell‐surface glycoprotein endosialin (tumor endothelial marker‐1[TEM‐1]/CD248) found on activated mesenchymal cells and certain tumors. Ontuxizumab binding to endosialin may interfere with platelet‐derived growth factor signaling, prevent tumor stroma organization, and prevent new vessel formation.MethodsOntuxizumab was administered intravenously on days 1, 8, 15, and 22 of a 28‐day cycle at three dose levels (4, 8, and 12 mg/kg). Further dose escalation to 16 mg/kg was planned if the maximum tolerated dose (MTD) was not reached and the ontuxizumab systemic clearance was ≥30% higher in children compared to adults. Following determination of the MTD/recommended phase 2 dose, an additional cohort of six patients (<12 years) was enrolled for further pharmacokinetics (PK) evaluation.ResultsTwenty‐seven eligible patients (17 male, median age 15 years, range 3–21 years) were enrolled. Twenty‐two patients (neuroblastoma [5], Ewing sarcoma [4], rhabdomyosarcoma [4], and other tumors [9]) were fully evaluable for toxicity. Five patients did not complete cycle 1 due to tumor progression. Two of 10 patients experienced dose‐limiting toxicity of bacteremia (n = 1) and hyponatremia (n = 1) at 12 mg/kg. Grade ≤2 fever or infusion‐related reactions occurred in 10 patients. Clearance was dose dependent and within 30% of adult value at 12 mg/kg.ConclusionOntuxizumab administered weekly at 12 mg/kg appears to be well tolerated in children with relapsed or refractory solid tumors. The PK of ontuxizumab does not appear to be significantly different in children compared to adults.
Defining the minimum clinically important difference for grade I degenerative lumbar spondylolisthesis: insights from the Quality Outcomes Database
Asher, Anthony L. , Kerezoudis, Panagiotis , Mummaneni, Praveen V. , Bisson, Erica F. , Glassman, Steven D. , Foley, Kevin T. , Slotkin, Jonathan R., Potts, Eric A. , Shaffrey, Mark E., Shaffrey, Christopher I. , Coric, Domagoj , Knightly, John J. , Park, Paul , Fu, Kai-Ming, Devin, Clinton J. , Archer, Kristin R. , Chotai, Silky , Chan, Andrew K. , Virk, Michael S. , Bydon, Mohamad

Mayo Clinic

Neurosurgical Focus | January 1, 2018 | Volume: 44 | Issue: 1 | Pages: E2

10.3171/2017.10.focus17554 | PMID 29290132 Get It

OBJECTIVE Patient-reported outcomes (PROs) play a pivotal role in defining the value of surgical interventions for spinal disease. The concept of minimum clinically important difference (MCID) is considered the new standard for determining the effectiveness of a given treatment and describing patient satisfaction in response to that treatment. The purpose of this study was to determine the MCID associated with surgical treatment for degenerative lumbar spondylolisthesis. METHODS The authors queried the Quality Outcomes Database registry from July 2014 through December 2015 for patients who underwent posterior lumbar surgery for grade I degenerative spondylolisthesis. Recorded PROs included scores on the Oswestry Disability Index (ODI), EQ-5D, and numeric rating scale (NRS) for leg pain (NRS-LP) and back pain (NRS-BP). Anchor-based (using the North American Spine Society satisfaction scale) and distribution-based (half a standard deviation, small Cohen’s effect size, standard error of measurement, and minimum detectable change [MDC]) methods were used to calculate the MCID for each PRO. RESULTS A total of 441 patients (80 who underwent laminectomies alone and 361 who underwent fusion procedures) from 11 participating sites were included in the analysis. The changes in functional outcome scores between baseline and the 1-year postoperative evaluation were as follows: 23.5 ± 17.4 points for ODI, 0.24 ± 0.23 for EQ-5D, 4.1 ± 3.5 for NRS-LP, and 3.7 ± 3.2 for NRS-BP. The different calculation methods generated a range of MCID values for each PRO: 3.3–26.5 points for ODI, 0.04–0.3 points for EQ-5D, 0.6–4.5 points for NRS-LP, and 0.5–4.2 points for NRS-BP. The MDC approach appeared to be the most appropriate for calculating MCID because it provided a threshold greater than the measurement error and was closest to the average change difference between the satisfied and not-satisfied patients. On subgroup analysis, the MCID thresholds for laminectomy-alone patients were comparable to those for the patients who underwent arthrodesis as well as for the entire cohort. CONCLUSIONS The MCID for PROs was highly variable depending on the calculation technique. The MDC seems to be a statistically and clinically sound method for defining the appropriate MCID value for patients with grade I degenerative lumbar spondylolisthesis. Based on this method, the MCID values are 14.3 points for ODI, 0.2 points for EQ-5D, 1.7 points for NRS-LP, and 1.6 points for NRS-BP.
Women fare best following surgery for degenerative lumbar spondylolisthesis: a comparison of the most and least satisfied patients utilizing data from the Quality Outcomes Database
Chan, Andrew K. , Bisson, Erica F. , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Potts, Eric A. , Shaffrey, Christopher I. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S., Kerezoudis, Panagiotis , Chotai, Silky , DiGiorgio, Anthony M. , Chan, Alvin Y. , Haid, Regis W., Mummaneni, Praveen V. , Fu, Kai-Ming, Virk, Michael S.

Mayo Clinic

Neurosurgical Focus | January 1, 2018 | Volume: 44 | Issue: 1 | Pages: E3

10.3171/2017.10.focus17553 | PMID 29290130 Get It

OBJECTIVE The American Association of Neurological Surgeons launched the Quality Outcomes Database (QOD), a prospective longitudinal registry that includes demographic, clinical, and patient-reported outcome (PRO) data, to measure the safety and quality of neurosurgical procedures, including spinal surgery. Differing results from recent randomized controlled trials have established a need to clarify the groups that would most benefit from surgery for degenerative lumbar spondylolisthesis. In the present study, the authors compared patients who were the most and the least satisfied following surgery for degenerative lumbar spondylolisthesis. METHODS This was a retrospective analysis of a prospective, national longitudinal registry including patients who had undergone surgery for grade 1 degenerative lumbar spondylolisthesis. The most and least satisfied patients were identified based on an answer of “1” and “4,” respectively, on the North American Spine Society (NASS) Satisfaction Questionnaire 12 months postoperatively. Baseline demographics, clinical variables, surgical parameters, and outcomes were collected. Patient-reported outcome measures, including the Numeric Rating Scale (NRS) for back pain, NRS for leg pain, Oswestry Disability Index (ODI), and EQ-5D (the EuroQol health survey), were administered at baseline and 3 and 12 months after treatment. RESULTS Four hundred seventy-seven patients underwent surgery for grade 1 degenerative lumbar spondylolisthesis in the period from July 2014 through December 2015. Two hundred fifty-five patients (53.5%) were the most satisfied and 26 (5.5%) were the least satisfied. Compared with the most satisfied patients, the least satisfied ones more often had coronary artery disease (CAD; 26.9% vs 12.2%, p = 0.04) and had higher body mass indices (32.9 ± 6.5 vs 30.0 ± 6.0 kg/m 2 , p = 0.02). In the multivariate analysis, female sex (OR 2.9, p = 0.02) was associated with the most satisfaction. Notably, the American Society of Anesthesiologists (ASA) class, smoking, psychiatric comorbidity, and employment status were not significantly associated with satisfaction. Although there were no significant differences at baseline, the most satisfied patients had significantly lower NRS back and leg pain and ODI scores and a greater EQ-5D score at 3 and 12 months postoperatively (p < 0.001 for all). CONCLUSIONS This study revealed that some patient factors differ between those who report the most and those who report the least satisfaction after surgery for degenerative lumbar spondylolisthesis. Patients reporting the least satisfaction tended to have CAD or were obese. Female sex was associated with the most satisfaction when adjusting for potential covariates. These findings highlight several key factors that could aid in setting expectations for outcomes following surgery for degenerative lumbar spondylolisthesis.
Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma
Nepal, Chirag , O’Rourke, Colm J. , Oliveira, Douglas V.N.P. , Taranta, A , Shema, Steven , Gautam, Prson , Caldéraro, Julien , Barbour, Andrew P. , Wennerberg, Krister , Wang, Xin Wei , Lautem, Anja , Roberts, Lewis R. , Andersen, Jesper B. , Roberts, Lewis R , Andersen, Jesper B , Wei Wang, Xin , Raggi, Chiara , Gautam, Prson , Wennerberg, Krister

Mayo Clinic

Hepatology | December 26, 2017 | Volume: 68 | Issue: 3 | Pages: 949-963

10.1002/hep.29764 | PMID 29278425 Get It

Intrahepatic cholangiocarcinoma remains a highly heterogeneous malignancy that has eluded effective patient stratification to date. The extent to which such heterogeneity can be influenced by individual driver mutations remains to be evaluated. Here, we analyzed genomic (whole‐exome sequencing, targeted exome sequencing) and epigenomic data from 496 patients and used the three most recurrently mutated genes to stratify patients ( IDH , KRAS , TP53 , “undetermined”). Using this molecular dissection approach, each subgroup was determined to possess unique mutational signature preferences, comutation profiles, and enriched pathways. High‐throughput drug repositioning in seven patient‐matched cell lines, chosen to reflect the genetic alterations specific for each patient group, confirmed in silico predictions of subgroup‐specific vulnerabilities linked to enriched pathways. Intriguingly, patients lacking all three mutations (“undetermined”) harbored the most extensive structural alterations, while isocitrate dehydrogenase mutant tumors displayed the most extensive DNA methylome dysregulation, consistent with previous findings. Conclusion : Stratification of intrahepatic cholangiocarcinoma patients based on occurrence of mutations in three classifier genes ( IDH , KRAS , TP53 ) revealed unique oncogenic programs (mutational, structural, epimutational) that influence pharmacologic response in drug repositioning protocols; this genome dissection approach highlights the potential of individual mutations to induce extensive molecular heterogeneity and could facilitate advancement of therapeutic response in this dismal disease. (H epatology 2018).
Augmented baroreflex heart rate gain after moderate-intensity, dynamic exercise
Halliwill, John R. , Taylor, J. Andrew , Eckberg, Dwain L. , Hartwig, Thomas , Taylor, J Andrew

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | December 24, 2017 | Volume: 270 | Issue: 2 | Pages: R420-R426

10.1152/ajpregu.1996.270.2.r420 | PMID 8779874 Get It

The occurrence of a sustained vasodilation and hypotension after acute, dynamic exercise suggests that exercise may alter arterial baroreflex mechanisms. Therefore, we assessed systemic hemodynamics, baroreflex regulation of heart rate, and cardiac vagal tone after 60 min of cycling at 60% peak oxygen consumption in 12 healthy, untrained men and women (ages 21-28 yr). We derived sigmoidal carotid-cardiac baroreflex relations by measurement of R-R interval changes induced by ramped, stepwise, R-wave-triggered changes in external neck pressure from 40 to -65 mmHg. We estimated tonic cardiac vagal control with power spectral analysis of R-R interval variability in the respiratory frequency band (0.2-0.3 Hz) during frequency- and tidal volume-controlled breathing. Both mean arterial pressure and total peripheral resistance were reduced postexercise [pressure: from 86 +/- 2 (mean +/- SE) to 81 +/- 2 mmHg; resistance: from 23 +/- 2 to 16 +/- 1 units; both P < 0.05]. Cardiac output was increased postexercise (from 3.9 +/- 0.3 to 5.5 +/- 0.5 l/min, P < 0.05). Both slope and range of the carotid-cardiac baroreflex relation were increased postexercise (slope: from 4.7 +/- 0.7 to 6.1 +/- 0.9 ms/mmHg; range: from 186 +/- 23 to 238 +/- 30 ms, P < 0.05). Respiratory R-R interval variability (cardiac vagal tone) was not changed at any time after exercise, whereas heart rate and plasma norepinephrine levels were elevated. Thus moderate-intensity, dynamic exercise increases heart rate and cardiac output, reduces peripheral vascular resistance, and augments baroreflex responsiveness. Our data suggest that augmented baroreflex heart rate gain restrains rather than contributes to postexercise hypotension, which appears to be mediated predominately by vasodilation.
Force relaxes before the fall of cytosolic calcium in the photomechanical response of rat sphincter pupillae
Krivoshik, Andrew, Barr, Lloyd

Mayo Clinic

American Journal of Physiology-Cell Physiology | December 24, 2017 | Volume: 279 | Issue: 1 | Pages: C274-C280

10.1152/ajpcell.2000.279.1.c274 | PMID 10898739 Get It

In the rat sphincter pupillae, as in other smooth muscles, the primary signal transduction cascade for agonist activation is receptor → G protein → phospholipase C → inositol trisphosphate → intracellular Ca2+ concentration ([Ca2+]i) → calmodulin → myosin light chain kinase → phosphorylated myosin → force development. Light stimulation of isolated sphincters pupillae can be very precisely controlled, and precise reproducible photomechanical responses (PMRs) result. This precision makes the PMR ideal for testing models of regulation of smooth muscle myosin phosphorylation. We measured force and [Ca2+]i concurrently in sphincter pupillae following stimulation by light flashes of varying duration and intensity. We sampled at unusually short (0.01–0.02 s) intervals to adequately test a PMR model based on the myosin phosphorylation cascade. We found, surprisingly, contrary to the behavior of intestinal muscle and predictions of the phosphorylation model, that during PMRs force begins to decay while [Ca2+]i is still rising. We conclude that control of contraction in the sphincter pupillae probably involves an inhibitory process as well as activation by [Ca2+]i.
Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM
Martinez‐Thompson, Jennifer M. , Snyder, Melissa R. , Ettore, Michael, McKeon, Andrew , Pittock, Sean J. , Roforth, Matthew M., Mandrekar, Jay , Mauermann, Michelle L. , Taylor, Bruce , Dyck, P. James B. , Windebank, Anthony J. , Klein, Christopher J. , Pittock, S J , Klein, Christopher J , McKeon, Andrew , Mauermann, Michelle L

Mayo Clinic

Muscle & Nerve | December 24, 2017 | Volume: 57 | Issue: 6 | Pages: 1000-1005

10.1002/mus.26051 | PMID 29272035 Get It

ABSTRACTIntroduction: Multifocal motor neuropathy (MMN) is a motor only, asymmetric onset neuropathy that is relatively treatment‐refractory compared with classic chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy. Methods: We reviewed 35 patients seropositive for GM1 (monosialo‐asialo [immunoglobulin M, IgM; immunoglobulin G, IgG]) and/or GD1b (disialo [IgG, IgM]) autoantibodies having MMN, classic CIDP, or MADSAM. Immune‐treatment responsiveness and clinical course was compared with antibody negative disease controls. Results: Seventy‐nine percent of seropositives with an initial diagnosis of MMN were immunotherapy responsive compared with 46% of seronegatives (P = 0.045). Eight ganglioside antibody positive MMN patients of 19 (42%) developed sensory findings consistent with MADSAM compared with 3 of 41 (7%) seronegative MMN patients (P = 0.003). MMN and MADSAM patients with ganglioside antibody positivity had more sustained treatment responses (P = 0.03). Discussion: Patients initially diagnosed with MMN seropositive for diverse GM1 autoantibodies appear more likely to have sustained treatment response and evolution to MADSAM. Muscle Nerve 57: 1000–1005, 2018
Calcium channel autoimmunity: Cerebellar ataxia and lambert‐eaton syndrome coexisting
Zalewski, Nicholas L. , Lennon, Vanda A. , Pittock, Sean J. , McKeon, Andrew , Zalewski, Nicholas, Pittock, S J , McKeon, Andrew

Mayo Clinic

Muscle & Nerve | December 24, 2017 | Volume: 58 | Issue: 1 | Pages: 29-35

10.1002/mus.26053 | PMID 29272039 Get It

ABSTRACTIntroduction: Neuronal calcium channel antibodies are a biomarker of Lambert‐Eaton syndrome (LES) and cerebellar ataxia. We have encountered several patients with LES and cerebellar ataxia coexisting, and we sought to further define this association. Methods: We reviewed records of patients at our institution with a diagnosis of “Lambert‐Eaton syndrome” and “cerebellar ataxia.” Results: Seventeen patients were identified with LES and ataxia. Presenting symptoms were weakness (8), concurrent weakness and ataxia (4), ataxia (4), and other (1). Nine patients had small‐cell lung carcinoma, 3 of whom had survival greater than 100 months. Immunotherapy responses were best among patients without cancer. Nine of 17 (53%) patients were alive at last follow‐up (median survival 62 months; range, 8–240). Discussion: Calcium channel autoimmunity should be considered in patients with coexisting cerebellar ataxia and myasthenic weakness. Affected patients may survive small‐cell carcinoma or have immunotherapy‐responsive neurological symptoms. Muscle Nerve 58: 29–35, 2018
Variations in muscle tone of the human rectum: recordings with an electromechanical barostat
Bell, Andrew M. , Pembérton, John H., Hanson, R, Zinsmeister, Alan R.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | December 24, 2017 | Volume: 260 | Issue: 1 | Pages: G17-G25

10.1152/ajpgi.1991.260.1.g17 | PMID 1987806 Get It

Rectal wall tone (the contractile state of the rectal tunica muscularis) should mediate accommodation and influence rectal emptying. Such changes in tone however can be only inferred from changes in baseline pressure recorded with conventional manometry. We used an isobaric volumetric device, the rectal electromechanical barostat, to quantify variations in tone of the rectal wall in response to feeding and to perturbations in response to the pharmacological agents neostigmine and glucagon. The barostat quantitates muscular wall tone indirectly by measuring its reciprocal, e.g., the volume of air within a flaccid intraluminal bag that is maintained at a constant and preselected pressure, by an electronic feedback mechanism. The barostat as well as a three-channel perfused manometric catheter were positioned in the rectum of 14 healthy volunteers. Three patterns of changes were observed: 1) respiratory fluctuations, 2) rapid volume waves, and 3) slow volume changes. Rectal tone varied little during fasting; rapid or slow changes in intrabag volume were infrequent. Ingestion of a standard meal was followed by a significant decrease in barostat bag volume (85 +/- 6 ml fasting vs. 50 +/- 8 ml fed, P less than 0.05). Pharmacological agents also induced predictable responses; neostigmine decreased bag volume and induced phasic pressure activity, whereas glucagon abolished phasic pressure activity and increased barostat bag volume. Perfused manometric catheters showed no concomitant changes in baseline pressure. We concluded that a rectal barostat measured variations in human rectal tone, which were not recorded by conventional manometric techniques. These changes in rectal tone might have important functional significance.